These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 20723627

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies.
    Zhai Y, Zhong Z, Zariffard M, Spear GT, Qiao L.
    Vaccine; 2013 Nov 04; 31(46):5422-9. PubMed ID: 24055348
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles.
    Zhang H, Huang Y, Fayad R, Spear GT, Qiao L.
    J Virol; 2004 Aug 04; 78(15):8342-8. PubMed ID: 15254206
    [Abstract] [Full Text] [Related]

  • 5. A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles.
    Meador LR, Kessans SA, Kilbourne J, Kibler KV, Pantaleo G, Roderiguez ME, Blattman JN, Jacobs BL, Mor TS.
    Virology; 2017 Jul 04; 507():242-256. PubMed ID: 28458036
    [Abstract] [Full Text] [Related]

  • 6. Mucosal antibodies induced by tandem repeat of 2F5 epitope block transcytosis of HIV-1.
    Wang J, Xu L, Tong P, Chen YH.
    Vaccine; 2011 Nov 03; 29(47):8542-8. PubMed ID: 21939723
    [Abstract] [Full Text] [Related]

  • 7. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity.
    Buonaguro L, Devito C, Tornesello ML, Schröder U, Wahren B, Hinkula J, Buonaguro FM.
    Vaccine; 2007 Aug 10; 25(32):5968-77. PubMed ID: 17629365
    [Abstract] [Full Text] [Related]

  • 8. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes.
    McBurney SP, Young KR, Ross TM.
    Virology; 2007 Feb 20; 358(2):334-46. PubMed ID: 17011011
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Heterologous HIV-based lentiviral/adenoviral vectors immunizations result in enhanced HIV-specific immunity.
    Asefa B, Korokhov N, Lemiale F.
    Vaccine; 2010 Apr 30; 28(20):3617-24. PubMed ID: 20051277
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation.
    Buonaguro L, Visciano ML, Tornesello ML, Tagliamonte M, Biryahwaho B, Buonaguro FM.
    J Virol; 2005 Jun 30; 79(11):7059-67. PubMed ID: 15890945
    [Abstract] [Full Text] [Related]

  • 15. Conformation-specific display of 4E10 and 2F5 epitopes on self-assembling protein nanoparticles as a potential HIV vaccine.
    Wahome N, Pfeiffer T, Ambiel I, Yang Y, Keppler OT, Bosch V, Burkhard P.
    Chem Biol Drug Des; 2012 Sep 30; 80(3):349-57. PubMed ID: 22650354
    [Abstract] [Full Text] [Related]

  • 16. Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines.
    Ye L, Wen Z, Dong K, Wang X, Bu Z, Zhang H, Compans RW, Yang C.
    PLoS One; 2011 Sep 30; 6(5):e14813. PubMed ID: 21625584
    [Abstract] [Full Text] [Related]

  • 17. Antigenic properties of a transport-competent influenza HA/HIV Env chimeric protein.
    Ye L, Sun Y, Lin J, Bu Z, Wu Q, Jiang S, Steinhauer DA, Compans RW, Yang C.
    Virology; 2006 Aug 15; 352(1):74-85. PubMed ID: 16725170
    [Abstract] [Full Text] [Related]

  • 18. Characterization of a trimeric MPER containing HIV-1 gp41 antigen.
    Hinz A, Schoehn G, Quendler H, Hulsik DL, Stiegler G, Katinger H, Seaman MS, Montefiori D, Weissenhorn W.
    Virology; 2009 Aug 01; 390(2):221-7. PubMed ID: 19539967
    [Abstract] [Full Text] [Related]

  • 19. Enhancing efficacy and mucosa-tropic distribution of an oral HIV-PsV DNA vaccine in animal models.
    Fu J, Bian G, Zhao B, Dong Z, Sun X, Chen F, Ou L, Song H.
    J Drug Target; 2009 Dec 01; 17(10):803-12. PubMed ID: 19863197
    [Abstract] [Full Text] [Related]

  • 20. Development and immunological assessment of VLP-based immunogens exposing the membrane-proximal region of the HIV-1 gp41 protein.
    Benen TD, Tonks P, Kliche A, Kapzan R, Heeney JL, Wagner R.
    J Biomed Sci; 2014 Aug 27; 21(1):79. PubMed ID: 25160824
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.